

**ALLEGATO B**

UNIVERSITÀ DEGLI STUDI DI MILANO

selezione pubblica per n. 1 posto di Ricercatore a tempo determinato ai sensi dell'art.24, comma 3, lettera a) della Legge 240/2010 per il settore concorsuale 06/D3 - Malattie del Sangue, Oncologia e Reumatologia, settore scientifico-disciplinare MED/06 - Oncologia Medica presso il Dipartimento di ONCOLOGIA ED EMATO-ONCOLOGIA (avviso bando pubblicato sulla G.U. n. 10 del 04/02/2020) Codice concorso 4261

**Carmen Criscitiello**  
**CURRICULUM VITAE**

**INFORMAZIONI PERSONALI (NON INSERIRE INDIRIZZO PRIVATO E TELEFONO FISSO O CELLULARE)**

COGNOME	CRISCITIELLO
NOME	CARMEN
DATA DI NASCITA	22/11/1980

**INSERIRE IL PROPRIO CURRICULUM**  
**(non eccedente le 30 pagine)**

Data

28/02/2020

Luogo

Milano

**FORMATO EUROPEO  
PER IL CURRICULUM  
VITAE**



**INFORMAZIONI PERSONALI**

Nome	<b>CARMEN CRISCITIELLO</b>
Indirizzo	VIA GALILEO GALILEI 6, 20124, MILANO, ITALIA
Telefono	02/57489599
Fax	02/94379224
E-mail	<a href="mailto:carmen.criscitiello@ieo.it">carmen.criscitiello@ieo.it</a> carmencriscitiello@hotmail.com
Nazionalità	Italiana
Data di nascita	22/11/1980

**ESPERIENZA LAVORATIVA**

Dal 2018 ad oggi	Dirigente medico di primo livello con incarico di Alta Specializzazione, Divisione e Sviluppo di Nuovi Farmaci per Terapie Innovative, Istituto Europeo di Oncologia Milano
2016	Visiting Phisician presso il Breast Cancer Department, Dana Farber Cancer Institute, Boston U.S.A.
Dal 2015 ad oggi	Dirigente medico di primo livello, Divisione e Sviluppo di Nuovi Farmaci per Terapie Innovative, Istituto Europeo di Oncologia Milano
2014	Visiting Researcher presso M.D. Anderson Cancer Center, Houston U.S.A.
2011-2014	Borsa di studio in Oncologia Medica, Divisione di Oncologia Medica, Istituto Europeo di Oncologia Milano
2009-2011	TransBIG Fellowship, Translational Research Unit, Institut Jules Bordet - Bruxelles, Belgium

**ISTRUZIONE E FORMAZIONE**

1999	Diploma di Maturità Classica presso il Liceo Ginnasio Statale Pietro Colletta, Avellino
2003-2005	Internato presso la Divisione di Oncologia Medica, Università degli Studi di Napoli Federico II
2005	Laurea in Medicina e Chirurgia presso l'Università degli Studi di Napoli "Federico II"
2006	Abilitazione all'esercizio della professione di Medico Chirurgo
2010	Specializzazione in Oncologia Medica presso l'Università degli Studi di Napoli "Federico II"
2013	Dottorato di Ricerca in Oncologia Medica e Chirurgica e Immunologia Clinica presso l'Università degli studi della Campania Luigi Vanvitelli

## **CAPACITÀ E COMPETENZE PERSONALI**

MADRELINGUA	<b>ITALIANO</b>
ALTRE LINGUE	
	<b>INGLESE</b>
• Capacità di lettura	eccellente
• Capacità di scrittura	eccellente
• Capacità di espressione orale	eccellente
	<b>FRANCESE</b>
• Capacità di lettura	eccellente
• Capacità di scrittura	eccellente
• Capacità di espressione orale	eccellente

## **CAPACITÀ E COMPETENZE RELAZIONALI**

	<b>DIREZIONE E PARTECIPAZIONE ALLE ATTIVITÀ DI GRUPPI DI RICERCA CARATTERIZZATI DA COLLABORAZIONI A LIVELLO NAZIONALE O INTERNAZIONALE</b>
2016	Partecipante della prima edizione di ESMO Leaders Generation Programme
Dal 2016 – ad oggi	Membro del Breast Cancer Working Group di Alleanza Contro il Cancro (ACC)
Dal 2017- ad oggi	Membro della ESMO Breast Cancer Faculty
Dal 2018- ad oggi	Membro della ESMO Press & Media Affairs Committee
Dal 2018- ad oggi	Estensore delle Linee Guida AIOM “Neoplasie della Mammella”
Dal 2020 – ad oggi	Vice Presidente della Task Force ESMO Leadership Generation
Dal 2020 – ad oggi	Membro del Molecular Tumor Board Working Group di Alleanza Contro il Cancro (ACC)

## **CAPACITÀ E COMPETENZE ORGANIZZATIVE**

2014	Membro della Commissione Scientifica per Metastatic Breast Cancer al congresso annuale ESMO
Dal 2018 – ad oggi	Associate Editor per la rivista scientifica ESMO Open - Cancer Horizons
Dal 2018 – ad oggi	Associate Editor per ESMO 2019 Congress Newspaper
Dal 2019 – ad oggi	Associate Editor per la rivista scientifica Frontiers in Oncology
Dal 2019 - ad oggi	Principal Investigator dello studio ALPHABET: A Randomized phase III trial of trastuzumab + ALPelisib +/- endocrine therapy versus trastuzumab + Chemotherapy in PIK3CA mutated HER2+ Advanced BrEasT cancer patients previously treated.

## CAPACITÀ E COMPETENZE ORGANIZZATIVE

2014	Membro della Commissione Scientifica per Metastatic Breast Cancer al congresso annuale ESMO
Dal 2018 – ad oggi	Associate Editor per la rivista scientifica ESMO Open - Cancer Horizons
Dal 2018 – ad oggi	Associate Editor per ESMO 2019 Congress Newspaper
Dal 2019 – ad oggi	Associate Editor per la rivista scientifica Frontiers in Oncology
Dal 2019 - ad oggi	Principal Investigator dello studio ALPHABET: A Randomized phase III trial of trastuzumab + ALPelisib +/- endocrine therapy versus trastuzumab + Chemotherapy in PIK3CA mutated HER2+ Advanced BrEasT cancer patients previously treated.

## CAPACITÀ E COMPETENZE TECNICHE

*Con computer, attrezzature specifiche, macchinari, ecc.*

Ottima competenza nell'uso e gestione di sistemi operativi Apple MacOS X e Windows e degli applicativi Windows Office (Word, Excel, Power Point) & Apple Office (Pages, Numbers, Keynote)

## ALTRE CAPACITÀ E COMPETENZE

Dal 2008 – ad oggi	Membro della European Society of Medical Oncology (ESMO)
Dal 2013 – ad oggi	Membro della Associazione Italiana di Oncologia Medica (AIOM)
oggi	Abilitazione Scientifica Nazionale alle funzioni di professore universitario di seconda fascia
2017	Premio per la miglior pubblicazione al congresso "Back from San Antonio"
2018	

## PATENTE O PATENTI

Patente tipo B

## ATTIVITÀ DIDATTICA A LIVELLO UNIVERSITARIO IN ITALIA O ALL'ESTERO

16/05/2013	Lezione dal titolo "Cancer Clinical Trials in the genomic era" per il "Corso di Translational Research and Clinical Trials" nell'ambito del "Structured International Post Doc program" (SIPOD) per la Scuola Europea di Medicina Molecolare (SEMM)
3/07/2013	Lezione dal titolo "New Drugs for breast cancer subtypes: targeting driver pathways to overcome resistance" per il corso di "From target to drug discovery", rivolta agli studenti del dottorato della la Scuola Europea di Medicina Molecolare (SEMM)
Giugno 2014	Seminario sul ruolo dei linfociti infiltranti il tumore (TILs) nel tumore mammario presso il laboratorio di Anatomia Patologica dell'M.D. Anderson Cancer Center, Houston U.S.A.
21/06/2016	Lezione per gli specializzandi di Oncologia Medica dell'Università degli studi di Milano dal titolo: "Treatment of endocrine responsive metastatic breast cancer: news from the 2016 ASCO annual meeting"
08/10/2019	Lezione per gli specializzandi di Oncologia Medica dell'Università degli studi di Milano dal titolo: "Post-ASCO/ESMO/AACR"
20/01/2020	Seminario per gli specializzandi di Oncologia Medica dell'Università degli studi della Campania Luigi Vanvitelli dal titolo: "Terapia sistemica del tumore mammario triple-negative"

## ULTERIORI INFORMAZIONI

Autore di 97 pubblicazioni su riviste scientifiche peer-reviewed

H-index = 25

Co-investigatore di oltre 100 studi clinici di fase I e fase II

Relatrice ad innumerevoli congressi nazionali ed internazionali

Nel 2017 ottenimento del Brevetto 16305838.1 "Use of the expression of specific genes for the prognosis of patients with triple negative breast cancer". Il brevetto è il risultato di un lavoro sul progetto TRANSCAN 2016, svolto in collaborazione tra l'Istituto Europeo di Oncologia e l'Istituto Gustave Roussy di Parigi. Abbiamo eseguito uno studio di next generation sequencing, con l'obiettivo di identificare e di validare su un ampio data set di campioni tumorali sequenziati, una gene signature che predice l'infiltrato linfocitario in pazienti con tumore triple-negative che ricevono chemioterapia neoadiuvante.

## PUBBLICAZIONI SCIENTIFICHE

1. **Criscitiello C**, Curigliano G. Tumour infiltrating lymphocytes and correlation with response to intensified platinum-based chemotherapy in BRCA-like tumours. *Eur J Cancer*. 2020
2. Curigliano G, Bagnardi V, Ghioni M, Louahed J, Brichard V, Lehmann FF, Marra A, Trapani D, **Criscitiello C**, Viale G. Expression of tumor-associated antigens in breast cancer subtypes. *Breast*. 2019
3. Punzi S, Balestrieri C, D'Alesio C, Bossi D, Dellino GI, Gatti E, Pruneri G, **Criscitiello C**, Lovati G, Meliksetyan M, Carugo A, Curigliano G, Natoli G, Pelicci PG, Lanfrancone L. WDR5 inhibition halts metastasis dissemination by repressing the mesenchymal phenotype of breast cancer cells. *Breast Cancer Res*. 2019
4. **Criscitiello C**, Viale G, Curigliano G. Harmonizing gene signatures to predict benefit from adjuvant chemotherapy in early breast cancer. *Curr Opin Oncol*. 2019
5. Park JH, Jonas SF, Bataillon G, **Criscitiello C**, Salgado R, Loi S, Viale G, Lee HJ, Dieci MV, Kim SB, Vincent-Salomon A, Curigliano G, André F, Michiels S. Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. *Ann Oncol*. 2019
6. Dieci MV, Del Mastro L, Cinquini M, Montemurro F, Biganzoli L, Cortesi L, Zambelli A, **Criscitiello C**, Levaggi A, Conte B, Calabrese M, Fiorentino A, Marchiò C, Tinterri C, Fittipaldo VA, Pappagallo G, Gori S. Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM). *Cancers (Basel)*. 2019 Aug 8;11(8).
7. Ochi T, Bianchini G, Ando M, Nozaki F, Kobayashi D, **Criscitiello C**, Curigliano G, Iwamoto T, Niikura N, Takei H, Yoshida A, Takei J, Suzuki K, Yamauchi H, Hayashi N. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer. *Eur J Cancer*. 2019
8. **Criscitiello C**, Curigliano G. Treatment in real-life patients with HER2-positive metastatic breast cancer: What we learn from the KAMILLA trial? *Eur J Cancer*. 2019
9. Punzi S, Meliksetian M, Riva L, Marocchi F, Pruneri G, **Criscitiello C**, Orsi F, Spaggiari L, Casiraghi M, Della Vigna P, Luzi L, Curigliano G, Pelicci PG, Lanfrancone L. Development of Personalized Therapeutic Strategies by Targeting Actionable Vulnerabilities in Metastatic and Chemotherapy-Resistant Breast Cancer PDXs. *Cells*. 2019
10. **Criscitiello C**, Viale G, Curigliano G. Peptide vaccines in early breast cancer. *Breast*. 2019
11. Esposito A, Viale G, **Criscitiello C**, Curigliano G. A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer. *Expert Rev Clin Pharmacol*. 2018
12. Preusser M, De Mattos-Arruda L, Thill M, **Criscitiello C**, Bartsch R, Ruhstaller T, de Azambuja E, Zielinski CC. CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion. *ESMO Open*. 2018 Aug 20
13. Malorni L, Curigliano G, Minisini AM, Cinieri S, Tondini CA, D'Hollander K, Arpino G, Bernardo A, Martignetti A, **Criscitiello C**, Puglisi F, Pestrin M, Sanna G, Moretti E, Risi E, Biagioni C, McCartney A, Boni L, Buyse M, Migliaccio I, Biganzoli L, Di Leo A. Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREN trial. *Ann Oncol*. 2018 Jun 11.
14. **Criscitiello C**, Santangelo M, Loupakis F. Cancer Immunotherapy and Identification of Prognostic and Predictive Biomarkers. *Biomed Res Int*. 2018 Mar 20

15. **Criscitiello C**, Golshan M, Barry WT, Viale G, Wong S, Santangelo M, Curigliano G. Impact of neoadjuvant chemotherapy and pathological complete response on eligibility for breast-conserving surgery in patients with early breast cancer: A meta-analysis. *Eur J Cancer*. 2018 Jul
16. Prager GW, Braga S, Bystricky B, Qvortrup C, **Criscitiello C**, Esin E, Sonke GS, Martínez GA, Frenel JS, Karamouzis M, Strijbos M, Yazici O, Bossi P, Banerjee S, Troiani T, Eniu A, Ciardiello F, Tabernero J, Zielinski CC, Casali PG, Cardoso F, Douillard JY, Jezdic S, McGregor K, Bricalli G, Vyas M, Ilbawi A. Global cancer control: responding to the growing burden, rising costs and inequalities in access. *ESMO Open*. 2018 Feb 2
17. Arruda LM, **Criscitiello C**, Lambertini M, Argiles G. ESMO Leaders Generation Programme: an alumni insight. *ESMO Open*. 2018 Jan 29
18. **Criscitiello C**, Viale G, Curigliano G, Goldhirsch A. Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date. *Breast Cancer (Dove Med Press)*. 2018 Jan 30
19. Duso BA, Trapani D, Viale G, **Criscitiello C**, D'Amico P, Belli C, Mazzarella L, Locatelli M, Minchella I, Curigliano G. Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer. *Expert Opin Pharmacother*. 2018 Feb;19
20. Di Cosimo S, Campbell C, Azim HA Jr, Galli G, Bregni G, Curigliano G, **Criscitiello C**, Izquierdo M, de la Pena L, Fumagalli D, Fein L, Vinholes J, Ng WMJ, Colleoni M, Ferro A, Naume BJ, Patel A, Huober J, Piccart-Gebhart MJ, Baselga J, de Azambuja. The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTO. *E. Eur J Cancer*. 2017 Dec 8.
21. **Criscitiello C**, Bagnardi V, Pruneri G, Vingiani A, Esposito A, Rotmensz N, Curigliano G. Prognostic value of tumour-infiltrating lymphocytes in small HER2-positive breast cancer. *Eur J Cancer*. 2017 Nov 15
22. Perri F, Buono G, Schettini F, Arpino G, Bianco R, **Criscitiello C**, De Placido S, Giuliano M. The Impact of Translational Research in Breast Cancer Care: Can We Improve the Therapeutic Scenario? *Anticancer Agents Med Chem*. 2017 Nov 2
23. **Criscitiello C**, Bayar MA, Curigliano G, Symmans FW, Desmedt C, Bonnefoi H, Sinn B, Pruneri G, Vicier C, Pierga JY, Denkert C, Loibl S, Sotiriou C, Michiels S, André F. A gene signature to predict high tumour-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple negative breast cancer. *Ann Oncol*. 2017 Oct 25
24. **Criscitiello C**, Viale G, Curigliano G. Extending indication of cyclin-dependent kinase 4/6 inhibitors in the adjuvant and neoadjuvant setting. *Curr Opin Oncol*. 2017 Nov;29
25. Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, **Criscitiello C**, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. *Adv Anat Pathol*. 2017 Aug 2
26. Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, **Criscitiello C**, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K,

- Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB. Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. *Adv Anat Pathol*. 2017 Sep;24
27. Solinas C, Carbognin L, De Silva P, **Criscitiello C**, Lambertini M. Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: Current state of the art. *Breast*. 2017 Jul 20
28. Trapani D, Esposito A, **Criscitiello C**, Mazzearella L, Locatelli M, Minchella I, Minucci S, Curigliano G. Entinostat for the treatment of breast cancer. *Expert Opin Investig Drugs*. 2017 Aug;26
29. Curigliano G, **Criscitiello C**. Maximizing the Clinical Benefit of Anthracyclines in Addition to Taxanes in the Adjuvant Treatment of Early Breast Cancer. *J Clin Oncol*. 2017 Aug 10.
30. Curigliano G, **Criscitiello C**, Esposito A, Intra M, Minucci S. Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer. *Expert Opin Drug Metab Toxicol*. 2017 Apr 11.
31. Esposito A, **Criscitiello C**, Trapani D, Curigliano G. The Emerging Role of "Liquid Biopsies," Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations. *Curr Oncol Rep*. 2017 Jan;19(1):1. doi: 10.1007/s11912-017-0564-y. Review.
32. Curigliano G, **Criscitiello C**, Esposito A, Pruneri G. Over-using chemotherapy in the adjuvant setting. *Breast*. 2017 Feb;31:303-308. doi: 10.1016/j.breast.2016.11.011.
33. Santangelo ML, Grifasi C, **Criscitiello C**, Giuliano M, Calogero A, Dodaro C, Incollongo P, Rupealta N, Candida M, Chiacchio G, Riccio E, Pisani A, Tammaro V, Carlomagno N. Bowel obstruction and peritoneal carcinomatosis in the elderly. A systematic review. *Aging Clin Exp Res*. 2016 Nov 11. [Epub ahead of print] Review. PMID: 27837464
34. **Criscitiello C**, Curigliano G, Burstein HJ, Wong S, Esposito A, Viale G, Giuliano M, Veronesi U, Santangelo M, Golshan M. Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity? *Eur J Surg Oncol*. 2016 Oct 29. pii: S0748-7983(16)30949-0. doi: 10.1016/j.ejso.2016.10.011. [Epub ahead of print] Review. PMID: 27825710
35. D'Alesio C, Punzi S, Cicalese A, Fornasari L, Furia L, Riva L, Carugo A, Curigliano G, **Criscitiello C**, Pruneri G, Pelicci PG, Faretta M, Bossi D, Lanfranccone L. RNAi screens identify CHD4 as an essential gene in breast cancer growth. *Oncotarget*. 2016 Oct 13. doi: 10.18632/oncotarget.12646. [Epub ahead of print] PMID: 27779108
36. **Criscitiello C**, Esposito A, Trapani D, Curigliano G. Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer. *Cancer Treat Rev*. 2016 Oct 6;50:205-207. doi: 10.1016/j.ctrv.2016.09.019. [Epub ahead of print] Review. PMID: 27744144
37. Fumagalli D, Wilson TR, Salgado R, Lu X, Yu J, O'Brien C, Walter K, Huw LY, **Criscitiello C**, Laios I, Jose V, Brown DN, Rothé F, Maetens D, Zardavas D, Savas P, Larsimont D, Piccart-Gebhart MJ, Michiels S, Lackner MR, Sotiriou C, Loi S. Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers. *Ann Oncol*. 2016 Oct;27(10):1860-6. doi: 10.1093/annonc/mdw286. PMID: 27672107
38. Migali C, Milano M, Trapani D, **Criscitiello C**, Esposito A, Locatelli M, Minchella I, Curigliano G. Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond. *Ther Adv Med Oncol*. 2016 Sep;8(5):360-74. doi: 10.1177/1758834016658423. Review. PMID: 27583028
39. Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Goulinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M; MINDACT Investigators. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. *N Engl J Med*. 2016 Aug 25;375(8):717-29. doi: 10.1056/NEJMoa1602253. PMID: 27557300
40. Pruneri G, Gray KP, Vingiani A, Viale G, Curigliano G, **Criscitiello C**, Láng I, Ruhstaller T, Gianni L, Goldhirsch A, Kammler R, Price KN, Cancelli G, Munzone E, Gelber RD, Regan MM, Colleoni M. Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.

Breast Cancer Res Treat. 2016 Jul;158(2):323-31. doi: 10.1007/s10549-016-3863-3. Epub 2016 Jul 2. PubMed PMID: 27372069.

41. **Criscitiello C**, Bagnardi V, Viale G, Disalvatore D, Rotmensz N, Esposito A, Goldhirsch A, Curigliano G. HER2 Equivocal Status in Early Breast Cancer Is Not Associated with Higher Risk of Recurrence. *Anticancer Res*. 2016 Jul;36(7):3537-40. PubMed PMID: 27354620.

42. **Criscitiello C**, Bagnardi V, Esposito A, Gelao L, Santillo B, Viale G, Rotmensz N, Goldhirsch A, Curigliano G. Impact of autoimmune diseases on outcome of patients with early breast cancer. *Oncotarget*. 2016 Jun 13. doi: 10.18632/oncotarget.9966. [Epub ahead of print] PubMed PMID: 27323400.

43. Curigliano G, Cardinale D, Dent S, **Criscitiello C**, Aseyev O, Lenihan D, Cipolla CM. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. *CA Cancer J Clin*. 2016 Jul;66(4):309-25. doi: 10.3322/caac.21341. Epub 2016 Feb 26. Review. PubMed PMID: 26919165.

44. Santangelo M, Esposito A, Tammaro V, Calogero A, **Criscitiello C**, Roberti G, Candida M, Rupealta N, Pisani A, Carlomagno N. What indication, morbidity and mortality for central pancreatectomy in oncological surgery? A systematic review. *Int J Surg*. 2016 Apr;28 Suppl 1:S172-6. doi: 10.1016/j.ijssu.2015.12.046. Epub 2015 Dec 18. Review. PubMed PMID: 26708862.

45. Esposito A, **Criscitiello C**, Locatelli M, Milano M, Curigliano G. Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies. *Pharmacol Ther*. 2016 Jan;157:120-4. doi: 10.1016/j.pharmthera.2015.11.007. Epub 2015 Nov 23. Review. PubMed PMID: 26615782.

46. Esposito A, **Criscitiello C**, Curigliano G. Immune checkpoint inhibitors with radiotherapy and locoregional treatment: synergism and potential clinical implications. *Curr Opin Oncol*. 2015 Nov;27(6):445-51. doi: 10.1097/CCO.0000000000000225. Review. PubMed PMID: 26447875.

47. **Criscitiello C**, Esposito A, De Placido S, Curigliano G. Targeting fibroblast growth factor receptor pathway in breast cancer. *Curr Opin Oncol*. 2015 Nov;27(6):452-6. doi: 10.1097/CCO.0000000000000224. Review. PubMed PMID: 26397764.

48. Esposito A, **Criscitiello C**, Gelao L, Pravettoni G, Locatelli M, Minchella I, Di Leo M, Liuzzi R, Milani A, Massaro M, Curigliano G. Mechanisms of anorexia-cachexia syndrome and rational for treatment with selective ghrelin receptor agonist. *Cancer Treat Rev*. 2015 Nov;41(9):793-7. doi: 10.1016/j.ctrv.2015.09.002. Epub 2015 Sep 11. Review. PubMed PMID: 26386985.

49. **Criscitiello C**, Curigliano G. Immunotherapy of Breast Cancer. *Prog Tumor Res*. 2015;42:30-43. doi: 10.1159/000437183. Epub 2015 Sep 4. Review. PubMed PMID: 26377084.

50. **Criscitiello C**, Giuliano M, Curigliano G, De Laurentiis M, Arpino G, Carlomagno N, De Placido S, Golshan M, Santangelo M. Surgery of the primary tumor in de novo metastatic breast cancer: To do or not to do? *Eur J Surg Oncol*. 2015 Oct;41(10):1288-92. doi: 10.1016/j.ejso.2015.07.013. Epub 2015 Jul 29. Review. PubMed PMID: 26238477.

51. Santangelo ML, **Criscitiello C**, Renda A, Federico S, Curigliano G, Dodaro C, Scotti A, Tammaro V, Calogero A, Riccio E, Pisani A, Carlomagno N. Immunosuppression and Multiple Primary Malignancies in Kidney-Transplanted Patients: A Single-Institute Study. *Biomed Res Int*. 2015;2015:183523. doi: 10.1155/2015/183523. Epub 2015 Jun 22. PubMed PMID: 26185750; PubMed Central PMCID: PMC4491567.

52. Dieci MV, **Criscitiello C**, Goubar A, Viale G, Conte P, Guarneri V, Ficarra G, Mathieu MC, Delalogue S, Curigliano G, Andre F. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. *Ann Oncol*. 2015 Jul;26(7):1518. doi: 10.1093/annonc/mdv241. PubMed PMID: 26109735.

53. Esposito A, **Criscitiello C**, Curigliano G. Neoadjuvant Model for Testing Emerging Targeted Therapies in Breast Cancer. *J Natl Cancer Inst Monogr*. 2015 May;2015(51):51-5. doi: 10.1093/jncimonographs/lgv012. PubMed PMID: 26063887.

54. Esposito A, **Criscitiello C**, Curigliano G. Highlights from the 14(th) St Gallen International Breast Cancer Conference 2015 in Vienna: Dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer. *Ecancermedicalscience*. 2015 Mar 31;9:518. doi: 10.3332/ecancer.2015.518. eCollection 2015. PubMed PMID: 25932042; PubMed Central PMCID: PMC4404037.

55. Curigliano G, Bagnardi V, Bertolini F, Alcalay M, Locatelli MA, Fumagalli L, Rabascio C, Calleri A, Adamoli L, **Criscitiello C**, Viale G, Goldhirsch A. Antiangiogenic therapy in recurrent breast cancer with lymphangitic spread to the chest wall: A randomized phase II trial of



bevacizumab with sequential or concurrent oral vinorelbine and capecitabine. *Breast*. 2015 Jun;24(3):263-71. doi: 10.1016/j.breast.2015.02.036. Epub 2015 Mar 12. PubMed PMID: 25772326.

56. Carlomagno N, Schonauer F, Tammaro V, Di Martino A, **Criscitiello C**, Santangelo ML. A multidisciplinary approach to an unusual medical case of locally advanced gastric cancer: a case report. *J Med Case Rep*. 2015 Jan 26;9:13. doi: 10.1186/1752-1947-9-13. PubMed PMID: 25619316; PubMed Central PMCID: PMC4407615.

57. **Criscitiello C**, Viale G, Gelao L, Esposito A, De Laurentiis M, De Placido S, Santangelo M, Goldhirsch A, Curigliano G. Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment. *Cancer Treat Rev*. 2015 Feb;41(2):61-8. doi: 10.1016/j.ctrv.2014.12.001. Epub 2014 Dec 8. Review. PubMed PMID: 25499997.

58. **Criscitiello C**, Esposito A, Curigliano G. Tumor-stroma crosstalk: targeting stroma in breast cancer. *Curr Opin Oncol*. 2014 Nov;26(6):551-5. doi: 10.1097/CCO.000000000000122. Review. PubMed PMID: 25279962.

59. Lammers P, **Criscitiello C**, Curigliano G, Jacobs I. Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets. *Pharmaceuticals (Basel)*. 2014 Sep 17;7(9):943-53. doi: 10.3390/ph7090943. PubMed PMID: 25232798; PubMed Central PMCID: PMC4190498.

60. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, Thompson EA, SymmansWF, Richardson AL, Brock J, **Criscitiello C**, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S; International TILs Working Group 2014. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. *Ann Oncol*. 2015 Feb;26(2):259-71. doi: 10.1093/annonc/mdl450. Epub 2014 Sep 11. PubMed PMID: 25214542.

61. **Criscitiello C**, Viale G, Esposito A, Curigliano G. Dinaciclib for the treatment of breast cancer. *Expert Opin Investig Drugs*. 2014 Sep;23(9):1305-12. doi: 10.1517/13543784.2014.948152. Epub 2014 Aug 8. Review. PubMed PMID: 25107301.

62. Esposito A, **Criscitiello C**, Salè EO, Curigliano G. Optimal adjuvant chemotherapy in breast cancer: selection of agents. *Expert Rev Clin Pharmacol*. 2014 Sep;7(5):605-11. doi: 10.1586/17512433.2014.945429. Epub 2014 Aug 1. Review. PubMed PMID: 25080998.

63. **Criscitiello C**, André F, Thompson AM, De Laurentiis M, Esposito A, Gelao L, Fumagalli L, Locatelli M, Minchella I, Orsi F, Goldhirsch A, Curigliano G. Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives. *Breast Cancer Res*. 2014;16(2):205. Review. PubMed PMID: 25032257; PubMed Central PMCID: PMC4052940.

64. Locatelli M, **Criscitiello C**, Esposito A, Minchella I, Goldhirsch A, Cipolla C, Curigliano G. QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review. *Target Oncol*. 2015 Mar;10(1):27-43. doi: 10.1007/s11523-014-0325-x. Epub 2014 Jun 27. Review. PubMed PMID: 24970120.

65. Ades F, Zardavas D, Pinto AC, **Criscitiello C**, Aftimos P, de Azambuja E. Cardiotoxicity of systemic agents used in breast cancer. *Breast*. 2014 Aug;23(4):317-28. doi: 10.1016/j.breast.2014.04.002. Epub 2014 May 1. Review. PubMed PMID: 24794210.

66. Gelao L, **Criscitiello C**, Esposito A, De Laurentiis M, Fumagalli L, Locatelli MA, Minchella I, Santangelo M, De Placido S, Goldhirsch A, Curigliano G. Dendritic cell-based vaccines: clinical applications in breast cancer. *Immunotherapy*. 2014;6(3):349-60. doi: 10.2217/imt.13.169. Review. PubMed PMID: 24762078.

67. Curigliano G, **Criscitiello C**. Successes and limitations of targeted cancer therapy in breast cancer. *Prog Tumor Res*. 2014;41:15-35. doi: 10.1159/000355896. Epub 2014 Feb 17. Review. PubMed PMID: 24727984.

68. **Criscitiello C**, Azim HA, de Azambuja E, Rubio IT. Factors affecting surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial. *Ann Oncol*. 2014 Apr;25(4):910-1. doi: 10.1093/annonc/mdl034. PubMed PMID: 24667722.

69. **Criscitiello C**, Gelao L, Viale G, Esposito A, Curigliano G. Investigational platelet-derived growth factor receptor kinase inhibitors in breast cancer therapy. *Expert Opin Investig Drugs*. 2014 May;23(5):599-610. doi: 10.1517/13543784.2014.895323. Epub 2014 Mar 5. Review. PubMed PMID: 24597540.

70. Gelao L, **Criscitiello C**, Esposito A, Goldhirsch A, Curigliano G. Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". *Toxins (Basel)*. 2014 Mar 3;6(3):914-33. doi: 10.3390/toxins6030914. Review. PubMed PMID: 24594636; PubMed Central PMCID: PMC3968368.
71. Dieci MV, **Criscitiello C**, Goubar A, Viale G, Conte P, Guarneri V, Ficarra G, Mathieu MC, Delaloge S, Curigliano G, Andre F. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. *Ann Oncol*. 2014 Mar;25(3):611-8. doi: 10.1093/annonc/mdt556. Epub 2014 Jan 8. Erratum in: *Ann Oncol*. 2015 Jul;26(7):1518. PubMed PMID: 24401929; PubMed Central PMCID: PMC3933248.
72. **Criscitiello C**, Esposito A, Gelao L, Fumagalli L, Locatelli M, Minchella I, Adamoli L, Goldhirsch A, Curigliano G. Immune approaches to the treatment of breast cancer, around the corner? *Breast Cancer Res*. 2014 Feb 25;16(1):204. doi: 10.1186/bcr3620. Review. PubMed PMID: 25774617; PubMed Central PMCID: PMC3978442.
73. **Criscitiello C**, Disalvatore D, De Laurentiis M, Gelao L, Fumagalli L, Locatelli M, Bagnardi V, Rotmensz N, Esposito A, Minchella I, De Placido S, Santangelo M, Viale G, Goldhirsch A, Curigliano G. High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer. *Breast*. 2014 Feb;23(1):69-75. doi: 10.1016/j.breast.2013.11.007. Epub 2013 Dec 4. PubMed PMID: 24314620.
74. Esposito A, Bardelli A, **Criscitiello C**, Colombo N, Gelao L, Fumagalli L, Minchella I, Locatelli M, Goldhirsch A, Curigliano G. Monitoring tumor-derived cell-free DNA in patients with solid tumors: clinical perspectives and research opportunities. *Cancer Treat Rev*. 2014 Jun;40(5):648-55. doi: 10.1016/j.ctrv.2013.10.003. Epub 2013 Oct 23. Review. PubMed PMID: 24184333.
75. **Criscitiello C**, Disalvatore D, Santangelo M, Rotmensz N, Bazolli B, Maisonneuve P, Goldhirsch A, Curigliano G. No link between breast cancer and meningioma: results from a large monoinstitutional retrospective analysis. *Cancer Epidemiol Biomarkers Prev*. 2014 Jan;23(1):215-7. doi: 10.1158/1055-9965.EPI-13-1041. Epub 2013 Oct 28. PubMed PMID: 24165579.
76. **Criscitiello C**, Curigliano G. Immunotherapeutics for breast cancer. *Curr Opin Oncol*. 2013 Nov;25(6):602-8. doi: 10.1097/CCO.000000000000020. Review. PubMed PMID: 24076578.
77. Curigliano G, **Criscitiello C**, Esposito A, Fumagalli L, Gelao L, Locatelli M, Minchella I, Goldhirsch A. Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium. *Breast*. 2013 Aug;22 Suppl 2:S96-9. doi: 10.1016/j.breast.2013.07.018. Review. PubMed PMID: 24074802.
78. Curigliano G, **Criscitiello C**, Esposito A, Fumagalli L, Gelao L, Locatelli M, Minchella I, Goldhirsch A. Best management of locally advanced inoperable breast cancer. *EJC Suppl*. 2013 Sep;11(2):289-90. doi: 10.1016/j.ejcsup.2013.07.052. Review. PubMed PMID: 26217148; PubMed Central PMCID: PMC4041552.
79. **Criscitiello C**. Tumor-associated antigens in breast cancer. *Breast Care (Basel)*. 2012 Aug;7(4):262-6. doi: 10.1159/000342164. PubMed PMID: 23904827; PubMed Central PMCID: PMC3515784.
80. Curigliano G, **Criscitiello C**, Gelao L, Goldhirsch A. Molecular pathways: human leukocyte antigen G (HLA-G). *Clin Cancer Res*. 2013 Oct 15;19(20):5564-71. doi: 10.1158/1078-0432.CCR-12-3697. Epub 2013 Jul 29. Review. PubMed PMID: 23897901.
81. Gelao L, **Criscitiello C**, Fumagalli L, Locatelli M, Manunta S, Esposito A, Minchella I, Goldhirsch A, Curigliano G. Tumour dormancy and clinical implications in breast cancer. *Ecancermedicalscience*. 2013 May 21;7:320. doi: 10.3332/ecancer.2013.320. Print 2013. PubMed PMID: 23717341; PubMed Central PMCID: PMC3660156.
82. Brollo J, Kneubil MC, Botteri E, Rotmensz N, Duso BA, Fumagalli L, Locatelli MA, **Criscitiello C**, Lohsiriwat V, Goldhirsch A, Leonardi MC, Orecchia R, Curigliano G. Locoregional recurrence in patients with HER2 positive breast cancer. *Breast*. 2013 Oct;22(5):856-62. doi: 10.1016/j.breast.2013.03.010. Epub 2013 May 1. PubMed PMID: 23642529.
83. Curigliano G, **Criscitiello C**, Andr  F, Colleoni M, Di Leo A. Highlights from the 13th St Gallen International Breast Cancer Conference 2013. Access to innovation for patients with breast cancer: how to speed it up? *Ecancermedicalscience*. 2013 Mar 26;7:299. doi: 10.3332/ecancer.2013.299. Print 2013. PubMed PMID: 23589728; PubMed Central PMCID: PMC3622446.

84. **Criscitiello C**, Azim HA Jr, Agbor-tarh D, de Azambuja E, Piccart M, Baselga J, Eidtmann H, Di Cosimo S, Bradbury I, Rubio IT. Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial. *Ann Oncol*. 2013 Aug;24(8):1980-5. doi: 10.1093/annonc/mdt129. Epub 2013 Apr 7. PubMed PMID: 23567146.
85. **Criscitiello C**, Curigliano G. HER2 signaling pathway and trastuzumab cardiotoxicity. *Future Oncol*. 2013 Feb;9(2):179-81. doi: 10.2217/fon.12.193. PubMed PMID: 23414468.
86. Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, **Criscitiello C**, Goldhirsch A, Cipolla C, Roila F; ESMO Guidelines Working Group. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. *Ann Oncol*. 2012 Oct;23 Suppl 7:vii155-66. PubMed PMID: 22997448.
87. **Criscitiello C**, Azim HA Jr, Schouten PC, Linn SC, Sotiriou C. Understanding the biology of triple-negative breast cancer. *Ann Oncol*. 2012 Aug;23 Suppl 6:vi13-8. Review. PubMed PMID: 23012296.
88. **Criscitiello C**, Metzger-Filho O, Saini KS, de Castro G Jr, Diaz M, La Gerche A, de Azambuja E, Piccart-Gebhart MJ. Targeted therapies in breast cancer: are heart and vessels also being targeted? *Breast Cancer Res*. 2012 Jun 19;14(3):209. Review. PubMed PMID: 22713170; PubMed Central PMCID: PMC3446327.
89. Brollo J, Curigliano G, Disalvatore D, Marrone BF, **Criscitiello C**, Bagnardi V, Kneubil MC, Fumagalli L, Locatelli M, Manunta S, Goldhirsch A. Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trials. *Cancer Treat Rev*. 2013 Feb;39(1):44-50. doi: 10.1016/j.ctrv.2012.03.009. Epub 2012 Apr 27. Review. PubMed PMID: 22541668.
90. Ignatiadis M, Singhal SK, Desmedt C, Haibe-Kains B, **Criscitiello C**, Andre F, Loi S, Piccart M, Michiels S, Sotiriou C. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. *J Clin Oncol*. 2012 Jun 1;30(16):1996-2004. doi: 10.1200/JCO.2011.39.5624. Epub 2012 Apr 16. PubMed PMID: 22508827.
91. Azim HA Jr, Michiels S, Bedard PL, Singhal SK, **Criscitiello C**, Ignatiadis M, Haibe-Kains B, Piccart MJ, Sotiriou C, Loi S. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. *Clin Cancer Res*. 2012 Mar 1;18(5):1341-51. doi: 10.1158/1078-0432.CCR-11-2599. Epub 2012 Jan 18. PubMed PMID: 22261811.
92. Curigliano G, Locatelli M, Fumagalli L, Brollo J, Munzone E, Nolé F, **Criscitiello C**, Goldhirsch A. Targeting the subtypes of breast cancer: rethinking investigational drugs. *Expert Opin Investig Drugs*. 2012 Feb;21(2):191-204. doi: 10.1517/13543784.2012.651456. Epub 2012 Jan 10. Review. PubMed PMID: 22229343
93. **Criscitiello C**, Fumagalli D, Saini KS, Loi S. Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection. *Onco Targets Ther*. 2010 Dec 17;4:1-11. doi: 10.2147/OTT.S10155. PubMed PMID: 21552410; PubMed Central PMCID: PMC3084302.
94. Ignatiadis M, Rothé F, Chaboteaux C, Durbecq V, Rouas G, **Criscitiello C**, Metallo J, Kheddoumi N, Singhal SK, Michiels S, Veys I, Rossari J, Larsimont D, Carly B, Pestrin M, Bessi S, Buxant F, Liebens F, Piccart M, Sotiriou C. HER2-positive circulating tumor cells in breast cancer. *PLoS One*. 2011 Jan 10;6(1):e15624. doi: 10.1371/journal.pone.0015624. PubMed PMID: 21264346; PubMed Central PMCID: PMC3018524
95. **Criscitiello C**, Sotiriou C, Ignatiadis M. Circulating tumor cells and emerging blood biomarkers in breast cancer. *Curr Opin Oncol*. 2010 Nov;22(6):552-8. doi: 10.1097/CCO.0b013e32833de186. Review. PubMed PMID: 20706122.
96. De Laurentiis M, **Criscitiello C**, Montanino A, Falato C, Plaitano M. [Exemestane in the treatment of breast carcinoma: recent findings]. *Tumori*. 2008 Jan-Feb;94(1):suppl 10-21. Italian. PubMed PMID: 18468352.
97. De Laurentiis M, Cancellò G, D'Agostino D, Giuliano M, Giordano A, Montagna E, Lauria R, Forestieri V, Esposito A, Silvestro L, Pennacchio R, **Criscitiello C**, Montanino A, Limite G, Bianco AR, De Placido S. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. *J Clin Oncol*. 2008 Jan 1;26(1):44-53. doi: 10.1200/JCO.2007.11.3787. PubMed PMID: 18165639.

**ATTIVITÀ DI RELATORE A CONGRESSI  
E CONVEGNI NAZIONALI E  
INTERNAZIONALI**

1. 13 febbraio 2020 San Antonio & Beyond, Rimini – Italy: "Immune checkpoint inhibitors in breast cancer"
2. January 10-11, 2020 Back From San Antonio. Genova – Italy: "New biologic findings in HER2+ breast cancer"
3. November 29, 2019 Molecular Pathology in interventional radiology - Monza, Italy: "NGS in breast cancer"
4. November 16, 2019 Breast Cancer Retreat - Naples, Italy: The role of CDK 4/6 inhibitors in clinical practice
5. October 26, 2019 AIOM annual meeting – Rome, Italy: oral presentation "Tumor Infiltrating Lymphocytes (TILs) in ER+/HER2- breast cancer"
6. October 18, 2019 W4O post-ESMO meeting – Naples, Italy: Breast cancer updates
7. October 11, 2019 SAMO Interdisciplinary Workshop on Breast Tumors- Lucerne, Switzerland: Recent Developments in Metastatic Breast Cancer (Immunotherapy)
8. October 4-5, 2019 AIOM Breast cancer, Rome – Italy: Treatment of metastatic HER2-positive breast cancer
9. September 28, 2019 ESMO annual meeting, Barcelona – Spain: poster discussion, breast cancer early stage
10. September 28, 2019 ESMO annual meeting, Barcelona – Spain: YO boxing session: De-escalation in early HER2+ breast cancer
11. September 20, 2019 The breast unit in Oncology, Bergamo Italy: metastatic triple negative breast cancer
12. September 12-13 2019 Going beyond in oncology Naples, Italy
13. June 14-15 2019 AIOM REVIEW: FROM CHICAGO TO VERONA Verona, Italy: Breast Cancer Poster Review
14. May 18-19, NAPLES LATE SPRING INTERACTIVE COURSE 2019, Naples-Italy: "Systemic treatment and metastatic disease: Luminal breast cancer"
15. May 18-19, NAPLES LATE SPRING INTERACTIVE COURSE 2019, Naples-Italy: "Systemic treatment and metastatic disease: HER2+ breast cancer"
16. May 4, 2019 ESMO Breast Cancer, Berlin – Germany: oral presenter "TILs in ER+/HER2- breast cancer"
17. May 4, 2019 ESMO Breast Cancer, Berlin – Germany: invited speaker "Immune therapy as a generalistic approach"
18. May 3, 2019 ESMO Breast Cancer, Berlin – Germany: ESMO WEBINAR Enhancing Immunogenicity in "Immune Excluded" or "Immune Desert" Breast Cancers
19. May 3, 2019 ESMO Breast Cancer, Berlin – Germany: session coordinator "Vesalius Talk: developing effective leadership skills"
20. March 19-20, 2019 DIVE Into Breast Care, Milano-Italy: "CDK4/6 inhibitors in postmenopausal women with metastatic breast cancer"
21. February 21-22, 2019 FOCUS SUL CARCINOMA MAMMARIO. Udine –Italy: "Top-five from ASCO/ESMO"
22. January 11-12, 2019 Back From San Antonio. Genova – Italy: "New biologic findings in HER2+ breast cancer"
23. November 28, 2018 1st European Course for MSd in training GOING BEYOND IN ONCOLOGY. Milano –Italy: "Integration of new drugs and old drugs into your clinical practice"
24. November 9, 2018 17th Stage in Medical Oncology. Taormina – Italy: "Breaking news in ER+ breast cancer"
25. October 27, 2018 Innovators in Breast Cancer. Baveno-Italy: "Round Table: The future of Breast Cancer Research: Young Oncologists Corner"
26. October 26, 2018 Carcinoma mammario i traguardi raggiunti e le nuove sfide. Roma-Italy: "Terapia sistemica adiuvante: quando e quale?"
27. October 13, 2018 Novità in carcinoma mammario, Bari-Italy: "Pazienti "triple positive": solo ormonoterapia e anti HER-2?"
28. June 26, 2018 IL PERCORSO CLINICO-ASSISTENZIALE PER LE DONNE CON TUMORE DELLA MAMMELLA - IX Edizione, Bologna-Italy: "La chemioterapia nel carcinoma mammario metastatico dopo antracicline e taxani in adiuvante: strategia nel 2018"

29. June 16, 2018 ESMO Leaders Generation Programme. Round Table Discussion in the session on W40: Women in Oncology. Lugano- Switzerland
30. June 16, 2018 invited talk at AIOM post ASCO, Milano- Italy: "ASCO Poster Review"
31. May 5-6, 2018 invited talk at Etna Late Spring Meeting 2018 Downsizing surgical treatment with systemic therapies. Giarre (Catania) – Italy: "primary systemic treatment: the very first therapeutic tool? Results from trials".
32. April 14-15, 2018 poster discussant at Okayama TR meeting. Okayama, Japan
33. March 24, 2018 chair at CANOA Project. "Breast Cancre: which news in 2018? How to interpret a clinical trial". Ospedaletto di Pescantina (VR) Italy
34. March 8, 2018 invited talk at Women for Women – , Rome Italy: "unmet need in metastatic breast cancer"
35. February 10, 2018 invited talk at BREASTorming – dalle evidenze alla pratica clinica nel BC HER2+, Napoli Italy: "Cosa dicono e non dicono le linee guida nel mBC HER2+"
36. February 8, 2018 invited talk at PALMARES – Palbociclib il primato dell'innovazione nel mBC, Roma Italy: "Palbociclib in HER2+ disease"
37. January 12, 2018 award and invited talk at "Back from San Antonio", Genova Italy: "A gene signature to predict high tumour-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple negative breast cancer"
38. December 14, 2017 invited speaker at the MBN 2017 Oncoplastic Breast Meeting, Milano Italy: "Primary systemic therapies"
39. September 10, 2017 invited speaker at the 2017 ESMO annual meeting, Madrid Spain: ESMO Clinical Practice Guidelines –"Patient with metastatic breast cancer: Sequence of therapies, case presentation"
40. September 9, 2017 oral presentation at the 2017 ESMO annual meeting, Madrid Spain: "A gene signature of chemo-immunization to predict outcome in patients with triple negative breast cancer treated with anthracycline-based neoadjuvant chemotherapy"
41. June 23, 2017 invited speaker at the 2017 Umberto Veronesi MBCC, Milano Italy: "Targeting DNA repair"
42. June 22, 2017 invited speaker at ESO Masterclass in Oncology Basics for Beginners Cambridge, UK: "Breast cancer: Outline of management"
43. June 22, 2017 invited speaker at ESO Masterclass in Oncology Basics for Beginners Cambridge, UK: "Abnormal CXR in a young female"
44. May 26, 2017 invited speaker at the "IL TRATTAMENTO DELLA PAZIENTE ANZIANA CON CARCINOMA MAMMARIO" Milano, Italy: therapeutic algorithm in elderly patients with Her2+ mBC
45. May 12th, 2017 invited speaker at 8th "Il Percorso Clinico-assistenziale per le donne con tumore della mammella" Bologna, Italy: Immunotherapy
46. March 21-23, 2017 invited speaker at 28th International Congress on Anti-Cancer Treatment (ICACT 2017) Paris, France: Genomic predictors of sensitivity to anti-PD1
47. March 15, 2017 St Gallen breast cancer conference in Vienna, Austria: Satellite symposium e cancer The coming of age for CDK 4/6 inhibitors, invited speaker on Clinical trial results: the benefits, side effects and costs.
48. November 16-17, 2016. Madrid, Spain: Everyday is precious MBC summit
49. October 17, 2016 invited speaker at EONS Dublin, Ireland: CDK 4/6 inhibitors: clinical data on breast trials.
50. July 7-9, 2016 panelist at Harvard CME course Breast Cancer: New Horizons, Current Controversies, Boston USA.
51. June 16-18, 2016 invited speaker at ESSO advanced course on oncoplastic breast surgery. Budapest, Hungary.
52. April 2016, invited speaker at "Giornate Salentine in Oncologia" Regional Meeting, Lecce Italy: from gene expression profiling to immunity and microenvironment in breast cancer
53. March 2016, invited speaker for European Society of Surgical Oncology Workshop at 10th European Breast Cancer Conference (EBCC-10), Amsterdam, The Netherlands: Value of Tumor-Infiltrating Lymphocytes in Neoadjuvant Treatment: Involvement in Prognosis and Pathologic Complete Response (pCR)
54. December 2015, invited speaker at Immuno-Oncology Regional Meeting, Salerno Italy: The role of immunotherapy in the Breast Cancer and Focus on TILs in the Breast Cancer

55. November 2015, invited speaker at HER2 + Breast Cancer: Challenges and Unanswered questions. BREAST CANCER PRECEPTORSHIP PROGRAMME. Medical Oncology Department. Ramon y Cajal University Hospital, Madrid, Spain
56. October 2014, invited speaker at ESSO, Liverpool UK: Debate: Which is Superior Neoadjuvant Therapy: Endocrine or Systemic Chemotherapy? Pro neoadjuvant chemotherapy
57. September 2014, invited speaker at ESMO, Madrid Spain: Contribution of immune response to anti-tumour effect of chemotherapy.
58. June 2014 invited speaker at MBCC, Milan Italy: Immunomarkers in early triple negative breast cancer.
59. June 2014 invited seminar at MDACC, Houston Texas: the role of tumor infiltrating lymphocytes in breast cancer.
60. May 2014 selected abstract for oral presentation at IMPAKT. Generation of mouse models for the identification of new driver pathways of drug resistance in human breast cancer (BC)
61. March 2014 Invited talk: Presentation of a Flims' protocol. Flims Alumni Club Session – Research Advances and Current Practice in the Management of Breast Cancer. EBCC9, Glasgow Scotland.
62. January 2014 Invited talk: "METASTASES: faut-il les biopsier?" Biennale Monégasque de Cancérologie, Cours Francophone d'Oncologie. Monaco
63. June 2013 Invited talk: "Chemotherapy benefit in Luminal breast cancer". Breast Cancer Progress and Controversies. Naples, Italy.
64. "The discrepancy between high pathological complete response (pCR) rate and low breast conserving surgery (BCS) following neoadjuvant therapy: analysis from the NeoALTTO trial (BIG 1-06)": abstract accepted for Proffered Paper (Oral) presentation during the ESMO 2012 Congress, 28 September - 2 October, Vienna, Austria.
65. 19-02-2011 Abstract accepted for oral presentation during BSMO (Belgian Society of Medical Oncology), Brussels, Belgium "More advanced stage Luminal A early breast cancers show distinct gene expression patterns associated with worse clinical outcome.
66. April 2010 Invited talk: "Biologics in adjuvant setting: where are we?" in: Winter Academy of Oncology: Early breast cancer, Pontresina, Switzerland.

Data 28/02/2020

Firma

